[{"id":"66ef3214-4b89-457d-8aec-3ac1952dab69","acronym":"","url":"https://clinicaltrials.gov/study/NCT03486119","created_at":"2021-01-18T17:10:17.329Z","updated_at":"2024-07-02T16:36:39.983Z","phase":"","brief_title":"A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients","source_id_and_acronym":"NCT03486119","lead_sponsor":"Yonsei University","biomarkers":" PD-L1 • CD8 • PD-1 • LAG3 • IL2RA • TIGIT • IL7R • NCAM1 • S100A8 • HMGB1 • ITGAM • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • LAG3 • IL2RA • TIGIT • IL7R • NCAM1 • S100A8 • HMGB1 • ITGAM • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 07/07/2020","primary_completion_date":" 07/07/2020","study_txt":" Completion: 07/07/2020","study_completion_date":" 07/07/2020","last_update_posted":"2020-10-19"},{"id":"9d13b4e5-4447-44e1-af76-2327291df5eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04520269","created_at":"2021-01-18T21:39:11.365Z","updated_at":"2024-07-02T16:36:41.807Z","phase":"Phase 1/2","brief_title":"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)","source_id_and_acronym":"NCT04520269","lead_sponsor":"National University Hospital, Singapore","biomarkers":" S100A8","pipe":"","alterations":" ","tags":["S100A8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2020-08-20"}]